The treatment with β-receptor blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and mineralocorticoid receptor antagonists (MRAs) reduce cardiovascular events and improve prognosis in patients with HF with reduced ejection fraction (HFrEF), while sodium/glucose cotransporter 2 (SGLT2) inhibitors reduce hospitalization and mortality risk in patients with HF with preserved ejection fraction (HFpEF) and HFrEF [2,3,4]. Here, SLC5A2 is linked to hydrops fetalis.